SJP 002

Drug Profile

SJP 002

Alternative Names: SJP002

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samjin Pharmaceutical Company
  • Class Anti-inflammatories; Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dry eyes

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Dry eyes (In volunteers) in South Korea (Ophthalmic) (NCT02924155)
  • 11 Jul 2016 Preclinical trials in Dry eyes in South Korea (Ophthalmic) before July 2016
  • 11 Jul 2016 Samjin Pharmaceutical receives clinical approval from Korean FDA for SJP 002 in Dry eyes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top